These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 26137204)

  • 1. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
    Chaidos A; Caputo V; Karadimitris A
    Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
    Cheung KL; Kim C; Zhou MM
    Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bromodomain: A New Target in Emerging Epigenetic Medicine.
    Smith SG; Zhou MM
    ACS Chem Biol; 2016 Mar; 11(3):598-608. PubMed ID: 26596782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
    Zhao Y; Yang CY; Wang S
    J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting bromodomains: epigenetic readers of lysine acetylation.
    Filippakopoulos P; Knapp S
    Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
    Alqahtani A; Choucair K; Ashraf M; Hammouda DM; Alloghbi A; Khan T; Senzer N; Nemunaitis J
    Future Sci OA; 2019 Mar; 5(3):FSO372. PubMed ID: 30906568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.
    Bechter O; Schöffski P
    Pharmacol Ther; 2020 Apr; 208():107479. PubMed ID: 31931101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain Protein Inhibitors Reorganize the Chromatin of Synovial Fibroblasts.
    Krošel M; Moser L; Houtman M; Friščić J; Tomšič M; Distler O; Hoffmann MH; Ospelt C; Klein K
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
    Chaidos A; Caputo V; Gouvedenou K; Liu B; Marigo I; Chaudhry MS; Rotolo A; Tough DF; Smithers NN; Bassil AK; Chapman TD; Harker NR; Barbash O; Tummino P; Al-Mahdi N; Haynes AC; Cutler L; Le B; Rahemtulla A; Roberts I; Kleijnen M; Witherington JJ; Parr NJ; Prinjha RK; Karadimitris A
    Blood; 2014 Jan; 123(5):697-705. PubMed ID: 24335499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
    Abedin SM; Boddy CS; Munshi HG
    Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
    Spriano F; Stathis A; Bertoni F
    Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.
    Padmanabhan B; Mathur S; Manjula R; Tripathi S
    J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.